Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites.
Bacterial translocation appears to be an important mechanism in the pathogenesis of spontaneous infections in cirrhosis. Cirrhotic patients are commonly treated with beta-adrenoceptor blockers, but the impact of this treatment in the factors promoting bacterial translocation has not been investigated. This study was aimed at investigating in cirrhotic rats with ascites the effect of propranolol on intestinal bacterial load, transit, and permeability of the bowel and on the rate of bacterial translocation. Bacterial translocation to mesenteric lymph nodes and intestinal bacterial overgrowth, permeability (urinary excretion of (99m)Tc-diethylenetriaminepentaacetic acid [(99m)Tc-DTPA]), and transit (geometric center ratio of (51)Cr) were assessed in 29 rats with carbon tetrachloride (CCl(4)) cirrhosis and 20 controls. These variables were then measured in 12 placebo- and in 13 propranolol-treated ascitic cirrhotic rats. Bacterial translocation was present in 48% of the cirrhotic rats and in none of the controls. Cirrhotic rats with intestinal bacterial overgrowth had a significantly higher rate of translocation and slower intestinal transit than those without it. Among the 15 rats with overgrowth and a (99m)Tc-DTPA excretion greater than 10%, 15 had translocation and 2 had bacterial peritonitis. Only 1 of the 14 rats with either intestinal overgrowth or a (99m)Tc-DTPA excretion greater than 10% presented translocation. Compared with the placebo group, propranolol-treated animals had significantly lower portal pressure, faster intestinal transit, and lower rates of bacterial overgrowth and translocation. In ascitic cirrhotic rats, bacterial translocation results from intestinal overgrowth and severe damage to gut permeability. In this setting, intestinal overgrowth is associated with intestinal hypomotility. Propranolol accelerates the intestinal transit, decreasing the rates of bacterial overgrowth and translocation.
Pérez-Paramo
M
M
Division of Nuclear Medicine, Clínica Puerta de Hierro, Madrid, Spain.
Muñoz
J
J
Albillos
A
A
Freile
I
I
Portero
F
F
Santos
M
M
Ortiz-Berrocal
J
J
D000818:Animals; D001419:Bacteria / Q000254:growth & development; D018988:Bacterial Translocation / Q000187:drug effects*; D002251:Carbon Tetrachloride; D007408:Intestinal Absorption; D007422:Intestines / Q000382:microbiology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000382:microbiology*; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D008643:Mesentery; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016284:Technetium Tc 99m Pentetate / Q000652:urine
D011433:Propranolol; D002251:Carbon Tetrachloride; D016284:Technetium Tc 99m Pentetate